Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Polifarma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880
Details : According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.
Brand Name : DA-3880
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Polifarma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?